National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation Provider Network RFP

Monday, August 29, 2016 Menīs Health News J E 4
Garretson Resolution Group seeking Providers to Participate

CINCINNATI, Aug. 29, 2016 /PRNewswire/ -- Garretson Resolution Group is issuing a Request for Proposal (RFP) seeking responses from providers who may wish to participate and provide medical evaluation as part of a class settlement program for the National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation.

On July 15, 2016, Judge John Z. Lee, United States District Judge for the District of Northern Illinois, granted preliminary approval to a settlement arising from In Re: National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation. The preliminary approval order also appointed Garretson as administrator of the proposed settlement's 50-year medical evaluation program.

The program will provide medical evaluations for class member current athletes and former athletes who are eligible to receive a medical evaluation consisting of a neurological examination, neuropsychological examination, mood and behavioral evaluation, and ancillary testing, as needed. This program is designed to assess current and former student-athletes so they may later seek treatment, if needed.

If you are interested in participating in this program, you may contact or click here to provide a few basic pieces of information. This is the first step in the process and is only to gauge interest. All requests must be received by September 28, 2016.

Founded in 1998, Garretson Resolution Group is a global provider of technology-enabled outsourced services to law firms, corporations, and government agencies. Garretson works closely with parties in large, complex matters to bring about creative solutions that include direct compensation, in-kind relief and medical monitoring to facilitate settlement objectives and processes.

Press Contact:

Stephanie Mulcahey



To view the original version on PR Newswire, visit:

SOURCE Garretson Resolution Group



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
FDA Grants Orphan-Drug Designation for Regenicin's...
ESC Congress 2016 Late Breaking Science Registry: ...